论文部分内容阅读
目前,美国食品与药物管理局(FDA)唯一批准用于治疗慢性丙型肝炎的药物是干扰素(IFN),用血清丙氨酸转氨酶(ALT)水平来评价已建立的IFN治疗方案,IFN的有效率为30％～40％,其中半数治疗有效者因中断IFN治疗而复发。若以丙型肝炎病毒(HCV)RNA的清除作为治疗有效的标准,有效率就更低了。目前一些用于IFN治疗无效的HCV感染者的治疗方法尚未标准化,已采用的方法有:再治疗更长一段时间;用三氮唑核苷单独或与IFN联合治疗;IFN加静脉切开术。每种方法各有其优缺点,因此均未被普遍接受。
Currently, the only drug approved by the U.S. Food and Drug Administration (FDA) for the treatment of chronic hepatitis C is interferon (IFN). Serum alanine aminotransferase (ALT) levels are used to evaluate established IFN regimens, and IFN Effective rate of 30% to 40%, of which half of the treatment-effective relapse due to interruption of IFN treatment. Clearance of hepatitis C virus (HCV) RNA as a therapeutically effective standard is even less effective. There are currently a number of treatments for HCV-infected individuals who are refractory to IFN therapy that have not been standardized and have been those that have been retreated for longer periods of time; ribavirin alone or in combination with IFN; and IFN plus phlebotomy. Each method has its own advantages and disadvantages, so they are not universally accepted.